The Prospera SCS system for pain management relieved pain, improved sleep and reduced opioid use at 24 months, according to ...

Teleflex, whose shares sank nearly 20% Thursday, will acquire most of Biotronik’s vascular intervention assets. Teleflex also ...

Medical devices provider, Teleflex (NYSE:TFX) said on Thursday that it will acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M, upon closing ...

Biotronik today announced a strategic shift that includes the divestiture of its Vascular Intervention (VI) business to Teleflex.

Acquisition of Biotronik’s vascular intervention business to sit under RemainCo Coinciding with the split announcement, Teleflex signed a deal to acquire Biotronik’s vascular intervention business ...

Teleflex (TFX) announced it has entered into a definitive agreement to acquire substantially all of the Vascular Intervention business of ...

Teleflex management announced a significant acquisition and business split, but the market reacted negatively. Read why I ...

Teleflex will acquire Biotronik's Vascular Intervention business for €760 million. Every week, our Whisper Index uncovers five overlooked stocks with big breakout potential. Get the latest picks today ...

In a flurry of news releases on Feb. 27, Teleflex Inc. reported plans to buy the vascular intervention business of Biotronik SE & Co. for €760 million (US$791 million), said it intended to split into ...

After the split, Teleflex would focus on devices for bloodstream and heart procedures, along with medical imaging, while ...

In addition, Teleflex said it agreed to pay about 760 million euros (about $791 million) to acquire nearly all of Biotronik’s vascular intervention division. The company also announced the ...

3 “We are excited to announce the acquisition of BIOTRONIK’s Vascular Intervention business, which we anticipate will significantly enhance our global presence in the cath lab, expand our ...